{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T14:01:44Z","timestamp":1789567304940,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T00:00:00Z","timestamp":1549238400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13014-019-1225-0","type":"journal-article","created":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T07:03:23Z","timestamp":1549263803000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Driving developments in UK oesophageal radiotherapy through the SCOPE trials"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7750-5320","authenticated-orcid":false,"given":"S.","family":"Gwynne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Poon King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Radhakrishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Wills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Staffurth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Crosby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,4]]},"reference":[{"key":"1225_CR1","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.clon.2014.06.001","volume":"26","author":"T Rackley","year":"2014","unstructured":"Rackley T, Leong T, Foo M, et al. Definitive Chemoradiotherapy for Oesophageal Cancer, a promising start on an exciting journey. Clin Oncol. 2014;26:533\u201340.","journal-title":"Clin Oncol"},{"key":"1225_CR2","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.clon.2014.05.015","volume":"26","author":"S Gwynne","year":"2014","unstructured":"Gwynne S, Wijnhoven B, Hulshof M, et al. Role of Chemoradiotherapy in Oesophageal Cancer - adjuvant and neoadjuvant therapy. Clin Oncol. 2014;26:522\u201332.","journal-title":"Clin Oncol"},{"key":"1225_CR3","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S1470-2045(13)70136-0","volume":"14","author":"T Crosby","year":"2013","unstructured":"Crosby T, Hurt C, Falk S, et al. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2\/3 randomised trial. Lancet. 2013;14:627\u201337.","journal-title":"Lancet"},{"key":"1225_CR4","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12885-015-1062-y","volume":"15","author":"S Mukherjee","year":"2015","unstructured":"Mukherjee S, Hurt C, Gwynne S, et al. NEOSCOPE: a randomised Phase II study of induction chemotherapy followed by either oxaliplatin\/capecitabine or paclitaxel\/carboplatin. based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma. BMC Cancer. 2015;15:48.","journal-title":"BMC Cancer"},{"key":"1225_CR5","unstructured":"SCOPE 2 Trials. 2017. \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02741856\n                    \n                  . Accessed Jan 2019."},{"key":"1225_CR6","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.clon.2012.06.010","volume":"24","author":"V K","year":"2012","unstructured":"K V, Tsang YCL, Coles CE, Yarnold JR. Does participation in clinical trials influence the implementation of new techniaues? A look at changing techniques in breast radiotherapy in the UK. Clin Oncol. 2012;24:100\u20135.","journal-title":"Clin Oncol"},{"key":"1225_CR7","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.ijrobp.2012.01.094","volume":"84","author":"S Gwynne","year":"2012","unstructured":"Gwynne S, Spezi E, Wills L, et al. Inter-observer variation in outlining of pre-trial test case in the SCOPE1 trial: a United Kingdom definitive Chemoradiotherapy trial for esophageal Cancer. Int J Radiat Oncol Biol Phys. 2012;84:1037\u201342.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1225_CR8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejca.2016.11.031","volume":"74","author":"S Mukherjee","year":"2017","unstructured":"Mukherjee S, Hurt C, Gwynne S, et al. NEOSCOPE: a randomised phase II study of induction chemotherapy followed by oxaliplatin\/capecitabine or carboplatin\/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma. Eur J Cancer. 2017;74:38\u201346.","journal-title":"Eur J Cancer"},{"key":"1225_CR9","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.clon.2013.01.006","volume":"25","author":"S Gwynne","year":"2013","unstructured":"Gwynne S, Falk S, Gollins S, et al. Oesophageal Chemoradiotherapy in the UK - current practice and future directions. Clin Oncol. 2013;25:368\u201377.","journal-title":"Clin Oncol"},{"key":"1225_CR10","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1259\/bjr.20160020","volume":"89","author":"S Gwynne","year":"2016","unstructured":"Gwynne S, Jones G, Maggs R, et al. Prospective review of radiotherapy trials through implementation of standardized multicentre workflow and IT infrastructure. Br J Radiol. 2016;89:1064.","journal-title":"Br J Radiol"},{"key":"1225_CR11","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.ijrobp.2014.06.028","volume":"90","author":"S Warren","year":"2014","unstructured":"Warren S, Partridge M, Carrington R, et al. Radiobiological determination of dose escalation and normal tissue toxicity in definitive chemoradiation therapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2014;90:423\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1225_CR12","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s13014-017-0916-7","volume":"12","author":"L Wills","year":"2017","unstructured":"Wills L, Maggs R, Lewis G, et al. Quality assurance of the SCOPE 1 trial in oesophageal radiotherapy. Radiat Oncol. 2017;12:179.","journal-title":"Radiat Oncol"},{"key":"1225_CR13","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.radonc.2012.02.010","volume":"103","author":"T Hong","year":"2012","unstructured":"Hong T, Tom\u00e9b W, Hararib P. Heterogeneity in head and neck IMRT target design and clinical practice. Radiother Oncol. 2012;103:92\u20138.","journal-title":"Radiother Oncol"},{"key":"1225_CR14","first-page":"S25","volume":"73","author":"MR Button","year":"2007","unstructured":"Button MR, Staffurth J, Crosby TDL. National variations in the treatment of oesophageal cancer with chemoradiotherapy. Clin Oncol. 2007;73:S25.","journal-title":"Clin Oncol"},{"key":"1225_CR15","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20120398","volume":"86","author":"S Gwynne","year":"2013","unstructured":"Gwynne S, Spezi E, Sebag-Montefiore D, et al. Improving radiotherapy quality assurance in clinical trials: assessment of target volume delineation of the pre-accrual benchmark case. Br J Radiol. 2013;86:20120398.","journal-title":"Br J Radiol"},{"key":"1225_CR16","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.radonc.2009.03.018","volume":"92","author":"O Matzinger","year":"2009","unstructured":"Matzinger O, Gerber E, Bernstein Z, et al. EORTC-ROG expert opinion: Radiotherapy volume and treatment guidelines for neoadjuvant radiation of adenocarcinomas of the gastroesophageal junction and the stomach. Radiother Oncol. 2009;92:164\u201375.","journal-title":"Radiother Oncol"},{"key":"1225_CR17","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.ijrobp.2008.04.062","volume":"73","author":"MR Button","year":"2009","unstructured":"Button MR, Morgan CA, Croydon ES, et al. Study to determine adequate margins in radiotherapy planning for esophageal carcinoma by detailing patterns of recurrence after definitive chemoradiotherapy. Int J of Radiat Oncol Biol Phys. 2009;73:818\u201323.","journal-title":"Int J of Radiat Oncol Biol Phys"},{"key":"1225_CR18","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.radonc.2007.07.008","volume":"84","author":"K Zhao","year":"2007","unstructured":"Zhao K, Liao Z, Bucci MK, et al. Evaluation of respiratory-induced target motion for esophageal tumors at the gastroesophageal junction. Radiother Oncol. 2007;84:283\u20139.","journal-title":"Radiother Oncol"},{"key":"1225_CR19","unstructured":"Matthews E, Bowden C, Nicholas O, et al. Radiation Therapy for Cancer of the Oesophagus and Pancreas, SMGroup, 2016. \n                    http:\/\/www.smgebooks.com\/Radiation-Oncology\/chapters\/RADO-16-03.pdf\n                    \n                  ."},{"key":"1225_CR20","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1053\/clon.2003.0218","volume":"15","author":"S Mukherjee","year":"2003","unstructured":"Mukherjee S, Aston D, Minett M, et al. The significance of cardiac doses received during Chemoradiation of Oesophageal and gastro\u2013oesophageal junctional cancers. Clin Oncol. 2003;15:115\u201320.","journal-title":"Clin Oncol"},{"key":"1225_CR21","first-page":"S33","volume":"17","author":"L Wills","year":"2005","unstructured":"Wills L, Lewis G, Passant H, et al. A Single-phase Versus Two-phase Conformal Planning Study for Oesophageal Radiotherapy. Clin Oncol. 2005;17:S33.","journal-title":"Clin Oncol"},{"key":"1225_CR22","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0167-8140(01)00438-8","volume":"61","author":"CM Nutting","year":"2001","unstructured":"Nutting CM, Bedford JL, Cosgrove VP, et al. A comparison of conformal and intensity modulated techniques for oesophageal radiotherapy. Radiother Oncol. 2001;61:157\u201363.","journal-title":"Radiother Oncol"},{"key":"1225_CR23","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.ijrobp.2012.02.015","volume":"5","author":"SH Lin","year":"2012","unstructured":"Lin SH, Wang L, Myles B, et al. Propensity score-based comparison of long-term outcomes with 3-dimensional conformal Radiotherapy vs intensity-modulated Radiotherapy for esophageal Cancer. Int J Radiat Oncol Biol Phys. 2012;5:1078\u201385.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1225_CR24","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.clon.2010.06.013","volume":"22","author":"J Staffurth","year":"2010","unstructured":"Staffurth J. A review of the clinical evidence for intensity-modulated Radiotherapy. Clin Oncol. 2010;22:643\u201357.","journal-title":"Clin Oncol"},{"key":"1225_CR25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejmp.2017.02.012","volume":"35","author":"D Eaton","year":"2017","unstructured":"Eaton D, Tyler J, Backshall A, et al. An external dosimetry audit programme to credential static and rotational IMRT delivery for clinical trials quality assurance. Phys Med. 2017;35:25\u201330.","journal-title":"Phys Med"},{"key":"1225_CR26","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.radonc.2009.08.036","volume":"93","author":"L Wills","year":"2009","unstructured":"Wills L, Millin A, Paterson J, et al. The effect of planning algorithms in oesophageal radiotherapy in the context of the SCOPE 1 trial. Radiother Oncol. 2009;93:462\u20137.","journal-title":"Radiother Oncol"},{"key":"1225_CR27","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.radonc.2010.11.002","volume":"98","author":"MA Hawkins","year":"2011","unstructured":"Hawkins MA, Aitken A, Hansen VN, et al. Set up errros for oesophageal cancers - is electronic portal imaging or conebeam more accurate? Radiother Oncol. 2011;98:249\u201354.","journal-title":"Radiother Oncol"},{"key":"1225_CR28","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.ijrobp.2009.05.045","volume":"77","author":"MA Hawkins","year":"2010","unstructured":"Hawkins MA, Brooks C, Hansen VN, et al. Cone beam computed tomography-derived adaptive radiotherapy for radical treatment of esophageal cancer. Int J Radiat Oncol Biol Phys. 2010;77:378\u201383.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1225_CR29","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.radonc.2012.08.008","volume":"105","author":"DC Weber","year":"2012","unstructured":"Weber DC, Tomsej M, Melidis C, et al. QA makes a clinical trial stronger: evidence-based medicine in radiation therapy. Radiother Oncol. 2012;105:4\u20138.","journal-title":"Radiother Oncol"},{"key":"1225_CR30","first-page":"S572","volume":"96","author":"E Miles","year":"2010","unstructured":"Miles E. A co-ordinated approach to national QA for multi Centre clinical trials: the UK RT trials QA group. Radiother Oncol. 2010;96:S572.","journal-title":"Radiother Oncol"},{"key":"1225_CR31","doi-asserted-by":"crossref","unstructured":"Rackley T, Caley A, Spezi E, et al. Oesophageal delineation - lessons learnt from pre-accrual benchmark cases in the UK NeoSCOPE oesophageal trial. Int J Radiat Oncol Biol Phys. 2014;90:S10.","DOI":"10.1016\/j.ijrobp.2014.05.088"},{"key":"1225_CR32","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1200\/jco.2016.34.4_suppl.119","volume":"34","author":"E Evans","year":"2016","unstructured":"Evans E, Jones G, Radhakrishna G, et al. On-trial radiotherapy quality assurance in NeoSCOPE: a randomised phase II trial of chemoradiotherapy in oesophageal cancer. J Clin Oncol. 2016;34:119.","journal-title":"J Clin Oncol"},{"key":"1225_CR33","doi-asserted-by":"crossref","unstructured":"Lave J, Wenger E. Communities of practice: learning, meaning and identity. Cambridge University Press; 1998.","DOI":"10.1017\/CBO9780511803932"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-019-1225-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13014-019-1225-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-019-1225-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T19:26:03Z","timestamp":1580757963000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-019-1225-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,4]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1225"],"URL":"https:\/\/doi.org\/10.1186\/s13014-019-1225-0","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,4]]},"assertion":[{"value":"29 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NA","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"NA","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"26"}}